Catheter-associated urinary tract infection (CAUTI) is the most common nosocomial infection. Each year, more than 1 million patients in U.S. acute-care hospitals and extended-care facilities acquire such an infection; the risk with short-term catheterization is 5% per day. CAUTI is the second most common cause of nosocomial bloodstream infection, and studies suggest that patients with CAUTI have an increased institutional death rate, unrelated to the occurrence of urosepsis. Novel urinary catheters impregnated with nitrofurazone or minocycline and rifampin or coated with a silver alloy-hydrogel exhibit antiinfective surface activity that significantly reduces the risk of CAUTI for short-term catheterizations not exceeding 2-3 weeks.

### Pathogenesis

Excluding rare hematogenously derived pyelonephritis, caused almost exclusively by *Staphylococcus aureus*, most microorganisms causing endemic CAUTI derive from the patient’s own colonic and perineal flora or from the hands of health-care personnel during catheter insertion or manipulation of the collection system. Organisms gain access in one of two ways (Figure 1). Extraluminal contamination may occur early, by direct inoculation when the catheter is inserted, or later, by organisms ascending from the perineum by capillary action in the thin mucous film contiguous to the external catheter surface. Intraluminal contamination occurs by reflux of microorganisms gaining access to the catheter lumen from failure of closed drainage or contamination of urine in the collection bag.

![Figure 1. Routes of entry of uropathogens to catheterized urinary tract.](image-url)
Recent studies suggest that CAUTIs most frequently stem from microorganisms gaining access to the bladder extraluminally, but both routes are important (Table 2) (16).

Some studies suggest that the extraluminal route may be of greater relative importance in women because of the short urethra and its close proximity to the anus (17). Investigators have found that antecedent heavy periurethral cutaneous colonization is an important risk factor for CAUTI in both men and women (17,18).

<table>
<thead>
<tr>
<th>Mechanism of CAUTI</th>
<th>Gram-positive cocci</th>
<th>Gram-negative bacilli</th>
<th>Yeasts</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extraluminal</td>
<td>79%</td>
<td>69%</td>
<td>54%</td>
<td>66%</td>
</tr>
<tr>
<td>Intraluminal</td>
<td>21%</td>
<td>31%</td>
<td>46%</td>
<td>34%</td>
</tr>
</tbody>
</table>

Percentages refer to organisms in which the mechanism of infection could be determined. For comparison of gram-positive cocci and yeasts vs. gram-negative bacilli, p = 0.007.

CAUTI = catheter-associated urinary tract infection.

Most infected urinary catheters are covered by a thick biofilm containing the infecting microorganisms embedded in a matrix of host proteins and microbial exoglycocalyx (Figure 2). A biofilm forms intraluminally, extraluminally, or both ways, usually advancing in a retrograde fashion (19). The role of the biofilm in the pathogenesis of CAUTI has not been established. However, antiinfective-impregnated and silver-hydrogel catheters (20-26), which inhibit adherence of microorganisms to the catheter surface, significantly reduce the risk of CAUTI, particularly infections caused by gram-positive organisms or yeasts, which are most likely to be acquired extraluminally from the periurethral flora (16). These data suggest that microbial adherence to the catheter surface is important in the pathogenesis of many, but not all, CAUTIs. Infections in which the biofilm does not play a pathogenetic role are probably caused by mass transport of intraluminal contaminants into the bladder by retrograde reflux of microbe-laden urine when a catheter or collection system is moved or manipulated (Figure 1, Table 2).

A prospective study in which catheterized patients were cultured daily by a technique capable of detecting very low-level bacteriuria, as low as 1 CFU/mL (7), showed that isolation of any microorganisms from an intraluminal specimen, even 3-4 CFU/mL, is highly predictive of CAUTI. If intercurrent antimicrobial therapy is not given, the level of bacteriuria or candiduria almost uniformly increases to >10^5 within 24-48 hours (Figure 3), demonstrating the vulnerability of the catheterized urinary tract to infection once any...
microorganisms gain access to the lumen of the catheter and the bladder. The very heavy use of systemic antimicrobial drugs in catheterized patients, which has been found in most studies (5-13), probably keeps the rate of CAUTI considerably lower than it would be otherwise, but unfortunately selects for the resistant organisms that produce most nosocomial CAUTIs (Table 1).

**Definition of CAUTI**

Most clinicians use a clean-voided specimen showing >10^5 CFU/mL as the criterion for “significant” bacteriuria (i.e., true infection) for noncatheterized patients (4). However, once any microorganisms are identified in urine from a patient’s indwelling catheter, unless suppressive antimicrobial-drug therapy is being given or started, progress to concentrations >10^5 CFU/mL occurs predictably and rapidly, usually within 72 hours (Figure 3) (7). Thus, most authorities consider concentrations >10^2 or 10^3 CFU/mL, in urine collected with a needle from the sampling port of the catheter, to be indicative of true CAUTI. This concentration can be reproducibly detected in the laboratory, and this definition is useful for therapeutic decisions and epidemiologic research (1-7).

**Risk Factors for CAUTI**

Large, prospective studies in which catheterized patients were cultured daily and which used multivariable techniques of statistical analysis identified risk factors independently predictive of increased risk for CAUTI (27-30; Table 3). Females have a substantially higher risk than males (relative risk [RR] 2.5-3.7), and patients with other active sites of infection (RR 2.3-2.4) or a major preexisting chronic condition (such as diabetes [RR 2.2-2.3], malnutrition [RR 2.4], or renal insufficiency [RR 2.1-2.6]) also are at higher risk. Inserting the catheter outside the operating room (RR 2.0-5.3) or late in hospitalization (RR 2.6-8.6), presence of a ureteral stent (RR 2.5), or using the catheter to measure urine output (RR 2.0) further increase the risk.

The most important, potentially modifiable risk factor, identified in every study, is prolonged catheterization, beyond 6 days (RR 5.1-6.8); by the 30th day of catheterization, infection is near-universal. A large, prospective study monitored compliance on a daily basis with seven recommended precepts for catheter care, including closed drainage, dependent drainage including proper position of the drainage tubing and collection bag, and protection of the drainage port; the only violation predictive of an increased risk of CAUTI was improper position of the drainage tube, above the level of the bladder or sagging below the level of the collection bag (RR 1.9) (27).

Antimicrobial-drug therapy has been shown to be protective against CAUTI for short-term catheterizations (RR 0.001-0.4) but clearly selects for infection caused by multidrug-resistant microorganisms, such as P. aeruginosa, and other resistant gram-negative bacilli, enterococci, and yeasts (Table 1) (1-10,15).

**Guidelines for Preventing CAUTI**

Several catheter-care practices are universally recommended to prevent or at least delay the onset of CAUTI: avoid unnecessary catheterizations; consider a condom or suprapubic catheter; have a trained professional insert the catheter aseptically; remove the catheter as soon as no longer needed; maintain uncompromising closed drainage; ensure dependent drainage; minimize manipulations of the system; and separate catheterized patients (1-4). However, few of these practices have been proven to be effective by randomized controlled trials.

**Avoid Unnecessary Catheterizations**

Use of indwelling urethral catheters should be limited to patients requiring relief of anatomic or physiologic outlet obstruction; patients undergoing surgical repair of the genitourinary tract (to facilitate healing); critically ill or postoperative patients who need their urinary output accurately measured; and debilitated, paralyzed, or comatose patients (to prevent skin breakdown and infected pressure ulcers). When no longer needed, the catheter should be promptly removed (31).

**Consider Alternatives to Urethral Catheterization**

Suprapubic catheterization is more comfortable and acceptable to the patient and may be associated with a lower incidence of CAUTI (32). For incontinent males who do not have bladder outlet obstruction, condom drainage, while not free from nosocomial urinary tract infections, appears to be associated with a lower risk than indwelling urethral catheters (33).

**Insertion Using Aseptic Technique**

Catheters should be inserted by trained health-care professionals using aseptic technique, including sterile gloves, a fenestrated sterile drape, and an effective cutaneous antiseptic, such as 10% povidone-iodine or 1% to 2% aqueous chlorhexidine.

**Closed Drainage**

After a catheter is inserted, uncompromising maintenance of closed drainage is of the highest priority and can keep the overall risk of CAUTI <25% for up to 2 weeks of catheterization (5,6).

**Ensure Dependent Drainage**

The collection tubing and bag should always remain below the level of the patient’s bladder, but the drainage tubing should always be above the level of the collection bag.

---

Table 3. Risk factors for catheter-associated urinary tract infection, based on prospective studies and use of multivariable statistical modeling (27-30)

<table>
<thead>
<tr>
<th>Factor</th>
<th>Relative risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prolonged catheterization &gt;6 days</td>
<td>5.1-6.8</td>
</tr>
<tr>
<td>Female gender</td>
<td>2.5-3.7</td>
</tr>
<tr>
<td>Catheter insertion outside operating room</td>
<td>2.0-5.3</td>
</tr>
<tr>
<td>Urology service</td>
<td>2.0-4.0</td>
</tr>
<tr>
<td>Other active sites of infection</td>
<td>2.3-2.4</td>
</tr>
<tr>
<td>Diabetes</td>
<td>2.2-2.3</td>
</tr>
<tr>
<td>Malnutrition</td>
<td>2.4</td>
</tr>
<tr>
<td>Azotemia (creatinine &gt;2.0 mg/dL)</td>
<td>2.1-2.6</td>
</tr>
<tr>
<td>Ureteral stent</td>
<td>2.5</td>
</tr>
<tr>
<td>Monitoring of urine output</td>
<td>2.0</td>
</tr>
<tr>
<td>Drainage tube below level of bladder and above collection bag</td>
<td>1.9</td>
</tr>
<tr>
<td>Antimicrobial-drug therapy</td>
<td>0.1-0.4</td>
</tr>
</tbody>
</table>
In one large prospective study, this was the only catheter-care violation associated with a significantly increased risk of CAUTI (RR 1.9) (27).

**Urine Collection**

The catheter and the drainage system should be manipulated as little as possible, and urine output should be monitored hourly only when clearly indicated by the patient's condition.

**Other Practices**

If feasible, separating catheterized patients geographically on a patient-care unit may reduce the risk of cross-infection with multidrug-resistant nosocomial organisms such as *Serratia, Klebsiella, Pseudomonas*, and *Enterobacter* (34).

Systemic antimicrobial prophylaxis with trimethoprim-sulfamethoxazole, methenamine mandelate or, especially, a fluoroquinolone, can reduce the risk of CAUTI for short-term catheterizations (35). Although use of antimicrobials in this way may reduce the rate of CAUTI, infections that do occur are far more likely to be caused by antibiotic-resistant bacteria and yeasts (1-10). Since most CAUTIs are asymptomatic and do not result in urosepsis (13), it is difficult to justify antimicrobial therapy of asymptomatic bacteriuria other than for granulocytopenic or other severely immunocompromised patients, patients scheduled for urologic surgery, pregnant women, patients with *Serratia* CAUTI, or patients about to have their catheter removed. The societal benefits of antibiotic prophylaxis in immunocompetent catheterized patients to prevent largely asymptomatic CAUTIs are dubious.

**Novel Technology**

Technologic innovations to prevent nosocomial infection are most likely to be most effective if they are based on a clear understanding of the pathogenesis and epidemiology of the infection (36). Novel technologies must be designed to block CAUTI by either the extraluminal or intraluminal routes or both (Figure 1). Technologic innovations have been proposed and evaluated during the past 25 years but have not proven conclusively beneficial (1-5). Among these innovations are using antifungal lubricants when inserting the catheter; soaking the catheter in an antifungal antiseptic solution before insertion; regular metal cleansing or periodically applying antifungal creams or ointments to metals; continuously irrigating the catheterized bladder with an antifungal solution through a triple-lumen catheter; or periodically instilling an antifungal solution into the collection bag (Table 4). Bladder irrigation with antifungal solutions has not only shown no benefit for preventing CAUTIs but has been associated with a paradoxically increased risk for CAUTI (30). The universal presence of a biofilm on the surface of an infected catheter (19) (Figure 2) has prompted hope that coating the catheter surface with an antiseptic, such as a silver compound, might reduce the risk for CAUTI. However, silver oxide-coated catheters, which had been initially reported to show promise, did not show efficacy when studied in large, well-controlled trials (29,30). In one of the trials, male patients with the coated catheter who did not receive systemic antibiotics had a paradoxical and inexplicably increased risk for CAUTI (30).

A silver-hydrogel catheter has been developed that inhibits adherence of microorganisms to the catheter surface in vitro; tested microorganisms include resistant enterococci, staphylococci, *Enterobacteriaceae*, *P. aeruginosa*, and yeasts (41). Small comparative but nonblinded trials have shown this product prevents CAUTI (22-25,42) (Figure 4). In a recent, large, double-blinded trial in 850 patients (26), the silver-hydrogel catheter reduced the incidence of CAUTI 26% (25.7 vs. 15.4 per 100 catheters, RR 0.74, p =0.04) (27). The greatest benefit was preventing infections caused by gram-positive organisms, enterococci and staphylococci (RR 0.45, p <0.001), and *Candida* (RR 0.80), microorganisms that usually gain access to the bladder extraluminally (16). The catheter conferred no protection against CAUTIs with gram-negative bacilli, which most often gain access intraluminally (16). Use of the silver-hydrogel catheter was not associated with an increased incidence of infections caused by antibiotic-resistant bacteria or *Candida*, and in vitro susceptibility testing of isolates from both treatment groups showed no infections caused by silver-resistant microorganisms. Cost-utility analysis indicates that use of this catheter could bring substantial cost savings to health-care institutions (Table 5).

**Table 4. Studies of novel technologies for preventing catheter-associated urinary tract infection**

<table>
<thead>
<tr>
<th>Technologic innovation (ref)</th>
<th>Risk reduction in randomized trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antifungal lubricant (2)</td>
<td>Unproven</td>
</tr>
<tr>
<td>Sealed catheter-collection tubing junctions (38-40)</td>
<td>Unproven</td>
</tr>
<tr>
<td>Antireflux valves (2)</td>
<td>Unproven</td>
</tr>
<tr>
<td>Continuous irrigation of bladder with antifungal solution (2,37)</td>
<td>Unproven</td>
</tr>
<tr>
<td>Instillation of antifungal into collection bag (2)</td>
<td>Unproven</td>
</tr>
<tr>
<td>Antifungal catheter material</td>
<td></td>
</tr>
<tr>
<td>Antimicrobial drug-impregnated Nitrofurazone (20)</td>
<td>0.7 (0.3⁰)</td>
</tr>
<tr>
<td>Minocycline-rifampin (21)</td>
<td>0.4</td>
</tr>
<tr>
<td>Silver oxide (29,30,42)</td>
<td>Unproven</td>
</tr>
<tr>
<td>Silver-hydrogel (22-25,26,42)</td>
<td>0.2-0.7</td>
</tr>
</tbody>
</table>

CAUTI = catheter-associated urinary tract infection.

*For bacterial CAUTI.*

**References**

drug resistant bacteria or yeasts (43) colonization and not to select for infection with antimicrobial-antibacterials to confer greater resistance to surface bacilli and staphylococci. Antiseptics are far more likely than urethral catheters; and vaccines for enteric gram-negative flux valves; urethral stents; conformable (collapsible) potent antiinfective materials; microbe-impervious antire-

Other technologies that should be pursued include new, more advances should not be considered the final answer, however.

The first major advance for preventing CAUTI since the wide-scale adoption of closed drainage 35 years ago is the development of catheters with ant Infectious Diseases: the pathogenesis, epidemiology, and prevention. Am J Med 1991;91(Suppl 3B):65S-71S.

Dr. Maki is professor of medicine and head of the Section of Infectious Diseases at the University of Wisconsin Medical School and hospital epidemiologist at University of Wisconsin Hospitals and Clinics. He has had a long interest in the pathogenesis, epidemiology, and prevention of nosocomial infections, particularly those caused by catheters or other implanted medical devices.

Dr. Tambyah, formerly a clinical and research fellow in infectious diseases at the University of Wisconsin Medical School, is assistant professor of medicine and consultant infectious disease physician at the University of Singapore School of Medicine and hospital epidemiologist at the National University Hospital of Singapore.

Table 5. Cost-benefit evaluation (restricted to direct hospital costs) of the silver-hydrogel catheter

<table>
<thead>
<tr>
<th>Assumptions of analysis</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of CAUTIs diagnosed clinically</td>
<td>65%</td>
</tr>
<tr>
<td>Cost of each diagnosed CAUTI</td>
<td>$1000a</td>
</tr>
<tr>
<td>Added acquisition cost of a silver-hydrogel catheter</td>
<td>$5</td>
</tr>
<tr>
<td>Incremental hospital costs, per 100 catheters:</td>
<td></td>
</tr>
<tr>
<td>Using standard urinary catheters</td>
<td>$17,000</td>
</tr>
<tr>
<td>(26 CAUTIs, 17 diagnosed)</td>
<td></td>
</tr>
<tr>
<td>Using silver-hydrogel catheters</td>
<td>$10,000</td>
</tr>
<tr>
<td>(15 CAUTIs, 10 diagnosed)</td>
<td></td>
</tr>
<tr>
<td>Added cost of catheters</td>
<td>$500b</td>
</tr>
<tr>
<td>Total costs</td>
<td>$10,500</td>
</tr>
<tr>
<td>Potential savings per 100 catheters</td>
<td>$6,500</td>
</tr>
</tbody>
</table>

aBased on studies showing that a diagnosed nosocomial CAUTI adds approximately $1,000 to direct costs of hospitalization (14); CAUTI = catheter-associated urinary tract infection.

bCost of preventing a CAUTI: approximately $71.

The Future

The first major advance for preventing CAUTI in the clinical setting of closed drainage 35 years ago is the development of catheters with ant infective surfaces. These advances should not be considered the final answer, however. Other technologies that should be pursued include new, more potent antinfective materials; microbe-impervious antireflux valves; urethral stents; conformable (collapsible) urethral catheters; and vaccines for enteric gram-negative bacilli and staphylococci. Antiseptics are far more likely than antibacterials to confer greater resistance to surface colonization and not to select for infection with antimicrobial-resistant bacteria or yeasts (43). New surface technologies that release far greater quantities of ionic silver or other antiinfective agents into the aqueous environment contiguous to the catheter surface might even prevent CAUTIs caused by intraluminal contaminants.

In uncontrolled trials, urethral stents have provided a less-invasive alternative to catheter drainage for men with outlet obstruction caused by prostatic hypertrophy or cancer (44). A conformable catheter, with a collapsible intraurethral segment that may cause less trauma to the urethra, has been developed but has not been tested clinically and is not commercially available. These and other alternatives to the rigid urethral catheter, such as a condom catheter for female patients (45), need to be evaluated in controlled, randomized trials.

The greatest hope for a major reduction in CAUTI and indeed all nosocomial infections is likely to be vaccines against important nosocomial multidrug-resistant pathogens, such as the enteric gram-negative bacilli and staphylococci.

References


